A carregar...

Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?

CT-P13, the world’s first biosimilar monoclonal antibody to infliximab, was approved for marketing in South Korea for all the six indications of infliximab, which Europe may follow, although the product was tested only in rheumatoid arthritis (RA) with a limited pharmacokinetic comparison in ankylos...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Autor principal: Lee, Howard
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2013
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3889539/
https://ncbi.nlm.nih.gov/pubmed/24114449
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1208/s12248-013-9534-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!